Pfizer Inc. (PFE) News

Pfizer Inc. (PFE): $52.47

1.82 (+3.59%)

POWR Rating

Component Grades













Filter PFE News Items

PFE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PFE News Highlights

  • PFE's 30 day story count now stands at 77.
  • Over the past 29 days, the trend for PFE's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
  • DRUG, AGE and MRNA are the most mentioned tickers in articles about PFE.

Latest PFE News From Around the Web

Below are the latest news stories about Pfizer Inc that investors may wish to consider to help them evaluate PFE as an investment opportunity.

4 Pharma Stocks to Buy Even if the Pandemic Ends

Here are four pharma stocks that looks attractive for the long-term.

Faisal Humayun on InvestorPlace | February 24, 2022

Novavax Is a Buy on Recent Developments and Cheap Valuation

NVAX stock is one of the major players in the vaccine market, which is one that is expected to grow substantially over the next few years.

Faizan Farooque on InvestorPlace | February 24, 2022

UPDATE 2-EMA backs Pfizer COVID booster for teens, Moderna shot for ages 6-11

The European Union's health regulator on Thursday backed giving a booster shot of Pfizer and BioNTech's COVID-19 vaccine to adolescents aged 12 and over, as well as the expanded use of Moderna's shot in children ages six to 11. The recommendations by the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use will be followed by final decisions by the European Commission. The moves come after several EU countries already started to offer booster doses of the Pfizer/BioNTech vaccine to teens.

Yahoo | February 24, 2022

Got $5,000? These 2 Growth Stocks Are Down 60% From Their Highs

Buying and holding quality growth stocks can be a surefire way to significantly increase your portfolio's value over the years. Two growth stocks that show lots of promise and are down more than 60% from their 52-week highs are BioNTech SE (NASDAQ: BNTX) and Matterport (NASDAQ: MTTR). Healthcare company BioNTech finished last week at less than $157 per share -- down more than 66% from the $464 it peaked at last Aug. 10, which was just after the release of its second-quarter results.

Yahoo | February 24, 2022

Moderna says booster protection wanes after 9 months

Moderna executives have revealed data showing that the protection afforded by its booster shot will begin to wane after about nine months, regardless of what vaccine a patient had used in the primary series.

Yahoo | February 24, 2022

10 Best Dividend Stocks to Buy According to Kahn Brothers

In this article, we discuss the 10 best dividend stocks to buy according to Kahn Brothers. You can skip our detailed analysis of the hedge fund’s investment philosophy, and go directly to read 5 Best Dividend Stocks to Buy According to Kahn Brothers. Kahn Brothers Group, an investment management firm, was founded by Irving Kahn, […]

Yahoo | February 24, 2022

4 Companies That Can Benefit From Buying Back More Stock

Pfizer, Nike, Walmart, and Broadcom are among the companies that have built up a war chest of cash and are considered prime buyback candidates.

Yahoo | February 24, 2022

COVID-19 shot interval can be extended to 8 weeks for some -U.S. CDC

Extending the interval between the first two doses of the most widely used COVID-19 vaccines in the country to eight weeks for young men can reduce the rare risk of heart inflammation, U.S. health officials said. The side effect, which has been linked to both Pfizer and Moderna's COVID-19 vaccines, is higher in 12- to 39-year-old men, and therefore the eight-week interval could be optimal for some people aged 12 years and older, the U.S. Centers for Disease Control and Prevention said on Tuesday. The recommended interval between the first two shots will remain three weeks for Pfizer's vaccine and four weeks for Moderna's vaccine in other population groups, the CDC said.

Yahoo | February 23, 2022

Sanofi-Glaxo Vaccine May Threaten Pfizer, Moderna in Covid-19 Booster Market

Sanofi and GlaxoSmithKline plan to submit their long-awaited Covid-19 vaccine for regulatory approval. Data suggest it's a contender against Pfizer and Moderna boosters.

Yahoo | February 23, 2022

Take Pfizer's $50 Billion Covid Payday With a Grain of Salt

In this clip from "The Health & Fitness Show" on Motley Fool Live, recorded on Feb. 11, Motley Fool contributors Brian Orelli, Meilin Quinn, and Sanmeet Deo talk about Pfizer's (NYSE: PFE) potential to hit $100 billion in total revenue and discuss how sustainable its stream of revenue is from its COVID-19 vaccine and treatment. Brian Orelli: So Pfizer doubled its revenue year-over-year, which was maybe not so surprising since it had sales of its vaccine for COVID-19 that basically that entire doubling was the COVID-19 vaccine.

Yahoo | February 23, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5254 seconds.